Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|93|3|401-407

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.93, Iss.3, 2018-03, pp. : 401-407

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 24, Iss. 4, 2001-09 ,pp. : 356-360

Karger

Access to resources Recommend Favorite

Combination therapy incorporating Bcl‐2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 2, 2018-02 ,pp. : 215-217

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Combination of Fludarabine, Cytarabine and Etoposide Is an Active and Well-Tolerated Regimen in Relapsed/Refractory Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 131, Iss. 4, 2013-11 ,pp. : 202-207

Karger

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 325-334

John Wiley & Sons Inc

Access to resources Recommend Favorite